Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sona Nanotech Inc C.SONA

Alternate Symbol(s):  SNANF

Technology Scientific & Technical Instruments
Sona Nanotech Inc. is a nanotechnology life sciences company that has developed multiple methods for the manufacturing of various types of gold nanoparticles. The Company is engaged in the research and development of its technology for use in multiplex diagnostic testing platforms and biomedical applications. Its gold nanotechnologies are adapted for use in applications, as a safe and delivery system for multiple medical treatments, for the approval of various regulatory boards, including Health Canada and the Food and Drug administration (FDA). Its gold nanorod particles are manufactured without the use of CTAB (cetyltrimethylammonium), eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. The Company leverages its core proprietary gold nanorod (GNR) manufacturing technology and laboratory assets to focus on the development of diagnostic tests and biologic reagents, and the advancement of its GNR intellectual property.


CSE:SONA - Post by User

Sona Nanotech Inc > Avacta still a ways off..
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1010)
•••
Comment by shoosh22on Jul 16, 2020 10:41am
101 Views
Post# 31275605

RE:RE: Avacta still a ways off..

RE:RE: Avacta still a ways off..Can you back that up with some facts pls.  Avacta Website under News says nothing about this.. except for what I posted below.  If prototype was optimized don't you think they would have said something..  Facts!  

What are you doing here... Go post on an Avacta forum if you are so keene on them.. but you are not... 

teaboy1 wrote:

Prototype of Avacta test was ready nearly 3 weeks ago. CEO stated in interview 2 weeks ago that the optimisation and transfer to the manufacturer will be in 2 weeks - so any day now...

They aren't as far away as you think you know... 

If Sona want to change their test to Saliva it will take quite a bit of development to change it... 



<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities